Engineering T Cells with a Tumor-Reactive Chimeric T Cell Receptor Reduces Exhaustion and Promotes Persistence to Elicit Enhanced Antitumor Responses - PubMed
12 hours ago
- #tumor microenvironment
- #MyD88 signaling
- #TCR-T cell therapy
- FDA approved the first TCR-T cell cancer therapy, but only a fraction of patients achieved long-lasting responses.
- A synthetic TCR was developed by appending CD3ζ and modified MyD88 to the β-chain of a tumor-reactive TCR.
- β:CD3ζ:MyD88 TCR-T cells showed enhanced functionality, reduced exhaustion, and promoted T cell persistence and expansion.
- These modified TCR-T cells skewed the tumor microenvironment to a less immunosuppressive state.
- β:CD3ζ:MyD88 TCR-T cells delayed tumor growth in a melanoma model.